Journal Article

Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases

  • Ernst S
  • Uzun S
  • Paats M
  • et al.
JCO Precision Oncology (2023) (7)
DOI: 10.1200/po.23.00451
3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Two cases show osimertinib/sotorasib combination could be effective in KRAS G12C-driven osimertinib resistance.

Cite

CITATION STYLE

APA

Ernst, S. M., Uzun, S., Paats, M. S., van Marion, R., Atmodimedjo, P. N., de Jonge, E., … Dingemans, A.-M. C. (2023). Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases. JCO Precision Oncology, (7). https://doi.org/10.1200/po.23.00451

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free